Stifel maintains Buy rating on Contineum Therapeutics stock despite MS trial failure
UNIONDALE, NY - ProPhase Labs, Inc. (NASDAQ:PRPH) announced Wednesday it is engaged in merger and acquisition discussions that could potentially recognize the company's value "at multiples of its current share price," according to a press release statement. The company, currently trading at $0.26 with a market cap of just $10.72 million, appears undervalued according to InvestingPro Fair Value estimates.
The company highlighted several value drivers it believes are undervalued by the market, including a $50 million Crown Medical collections initiative, commercialization of its BE-Smart Esophageal Cancer Test, and its now-profitable Nebula Genomics subsidiary.
ProPhase reported that Crown Medical Collections has been formally appointed as Special Counsel following bankruptcy court approval of its subsidiaries' Chapter 11 proceedings, allowing litigation to begin directly against insurance carriers. One claim has already been resolved, with the company anticipating "meaningful settlements within the next few months."
The company is also advancing commercialization of its BE-Smart esophageal cancer risk-stratification assay following a validation study published in Clinical and Translational Gastroenterology. The Mayo Clinic-led study provided independent validation of the test's accuracy in Barrett's esophagus risk detection.
"The public markets are not yet reflecting the true value of ProPhase or the multi-year opportunities now in front of us," said Ted Karkus, CEO and Chairman, in the press release. This sentiment aligns with InvestingPro analysis, which shows the stock has fallen 65.9% year-to-date and is trading at just 0.94 times book value. InvestingPro offers several additional insights on PRPH's financial health and prospects in its comprehensive Pro Research Report.
For the third quarter ended September 30, 2025, ProPhase reported net revenue of $0.9 million compared to $1.4 million in the same period of 2024. The company posted a net loss from continuing operations of $6.8 million, or $(0.16) per share, compared to a loss of $5.0 million, or $(0.26) per share, in the prior-year quarter. Investors watching for potential improvement can mark November 19, 2025, when the company is scheduled to release its next earnings report.
As of September 30, 2025, ProPhase had cash and cash equivalents of $405,000, down from $678,000 at the end of 2024. InvestingPro identifies this as a concern, noting the company is "quickly burning through cash" and "operates with a significant debt burden" with a debt-to-equity ratio of 0.69.
In other recent news, ProPhase Labs, Inc. reported significant developments across several areas. The company announced that its BE-Smart test for Barrett's Esophagus achieved 100% sensitivity in identifying patients who later developed esophageal cancer, as confirmed by a study in collaboration with Mayo Clinic. Additionally, ProPhase Labs disclosed that its COVID-19 testing subsidiaries have filed for Chapter 11 bankruptcy protection, citing substantial amounts owed by insurance companies for completed testing services. This filing pertains only to the COVID-19 lab units and does not involve the parent company or its other divisions.
In a strategic move, ProPhase Labs has entered into an agreement with ThinkEquity LLC for a $6 million private placement, focusing on its digital asset treasury strategy. This agreement designates ThinkEquity as the exclusive strategic advisor and placement agent. Furthermore, the company is exploring potential investments in digital assets following shareholder approval of related proxy items. Lastly, ProPhase Labs reminded shareholders of an upcoming Special Meeting of Stockholders scheduled for November 24, 2025, emphasizing the importance of voting before the proxy deadline.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.